-
1 Comment
Circassia Group Plc is currently in a long term downtrend where the price is trading 53.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Finally, its free cash flow grew by 34.3% to $-2M since the same quarter in the previous year.
Based on the above factors, Circassia Group Plc gets an overall score of 2/5.
Exchange | LSE |
---|---|
CurrencyCode | GBP |
Sector | Healthcare |
Industry | Medical Devices |
ISIN | GB00BJVD3B28 |
Beta | 1.56 |
---|---|
Market Cap | 143M |
PE Ratio | 34.0 |
Target Price | 47 |
Dividend Yield | 0.0% |
Circassia Group Plc, a medical device company, focuses on the respiratory diagnostics and monitoring products in the United States, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It offers NIOX and NIOX VERO, a fractional exhaled nitric oxide measurement and monitoring products for use in asthma diagnosis and management. The company offers its products approximately in 50 countries through a network of distribution partners. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CIR.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025